1. Tay J, Ruiz A, Schenone H, Robert L, Sanchez-Vega JT, Uribarre T, Becerril MA, Romero R, 1994. Frequency of intestinal protozoosis in the Mexican Republic. Bol Chil Parasitol 49:9–15.
2.  Tellez A, Morales W, Rivera T, Meyer E, Leiva B, Linder E, 1997. Prevalence of intestinal parasites in the human population of Leon, Nicaragua. Acta Trop 66: 119–125.
3. Rezende CH, Costa-Cruz JM, Gennari-Cardoso ML, 1997. Enteroparasitoses in food handlers of the public schools in Uberlandia (Minas Gerais), Brazil. Rev Panam Salud Publica 2:392–397.
4. Tay J, Ruiz A, Sanchez-Vega JT, Romero-Cabello R, Robert L, Becerril MA, 1995. Intestinal helminthiasis in the Mexican Republic. Bol Chil Parasitol 50: 10–16.
5. Devera R, Niebla-Punos G, Nastasi-Vatanese JA, Velásquez- Álvarez VJ, González-Menéses R, 1998. Giardiasis en escolares de Ciudad Bolívar, Estado Bolívar, Venezuela. Rev Biomed 9: 145–150.
6. Instituto Nacional de Diagnostico y Referencia Epidemiológicos, 1994. Encuestas Centinelas para la evaluación de la eficacia de la quimioterapia masiva contra helmintos intestinales de octubre de 1993. México: Instituto Nacional de Diagnóstico y Referencia Epidemiológicos, Subsecretaría de Coordinación y Desarrollo.
7. Romero-Cabello R, Quiñonez-Vega E, Manrique JJ, 1991. Valoración terapéutica de la quinfamida en amibiasis intestinal con un solo día de tratamiento. Compendium de Investigaciones Clínicas Latinoamericanas 2: 14.
8. Baker JF, O’Melia PE, Benziger DP, Clemans SD, Edelson J, 1982. The disposition of quinfamide in the rat. Arch Int Pharmacodyn 258: 29–38.
9. Pantoja G, 1993. Evaluación de la quinfamida en el tratamiento antiamibiano de un día. Investigación Médica Internacional 20: 3–7.
10. Touze JE, 1994. Present status and new approach to anti-parasite therapy. Presse Med 23: 1195–1198.
11. Albonico M, Crompton DW, Savioli L, 1999. Control strategies for human intestinal nematode infections. Adv Parasitol 42: 277–341.
12. Cavier ET, Rossignol JF, 1982. E ´ tude pharmacologique de diverses associations’ d’anthelminthiques. Rev Med Vet 133: 779– 783.
13. Murphy JR, Friedmann, 1985. Pre-clinical toxicology of nitazoxanide- a new antiparasitic compound. J Appl Toxicol 5: 49–52.
14. Rossignol JF, 1994. Nitazoxanide: a new broad spectrum antibacterial- antiparasiticidal drug: pre-clinical pharmacology. J Trop Med 3: 1–6.
15. Kabil SM, El-Salam FA, Nassar AK, El-Bast AM, 1994. Phase II: effects of nitazoxanide on the treatment of common human helminthic and protozoal infections. J Trop Med 3: 7–10.
16. Stockis A, Deroubaix X, Lins R, Jeanbaptiste B, Calderon P, Rossignol JF, 1996. Pharmacokinetics of nitazoxanide after single oral dose administration in 6 healthy volunteers. Int J Clin Pharmacol Ther 34: 349–351.
17. Rossignol JF, Maisonneuve H, 1984. Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana infections. Am J Trop Med Hyg 33: 511–512.
18. Dubreuil L, Houcke I, Moulton Y, Rossignol JF, 1996. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organism. Antimicrob Agents Chemother 40: 2266–2270.
19. Doumbo O, Rossignol JF, Pichard E, Traore HA, Dembele TM, Diakite M, Traore F, Diallo DA, 1997. Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Am J Trop Med Hyg 56: 637–639.
20. Romero-Cabello R, Guerrero LR, Muñoz-García MR,  Geyne- Cruz A, 1997. Nitazoxanide for the treatment of intestinal protozoan and helminthic infections in Mexico. Trans R Soc Trop Med Hyg 91: 701–703.
21. Theodos CM, Griffiths JK, D’Onfro J, Fairfield A, Tzipori S, 1998. Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models. Antimicrob Agents Chemother 42: 1959–1965.
22. Rossignol JF, Abaza H, Friedman H, 1998. Successful treatment of human fascioliasis with nitazoxanide. Trans R Soc Trop Med Hyg 92: 103–104.
23. Megraud F, Occhialini A, Rossignol JF, 1998. Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole. Antimicrob Agents Chemother 42: 2836–2840.
24.  Rosssignol JF, Hidalgo H, Feregrino M, Higuera F, Gomez WH, Romero JL, Padierna J, Geyne A, Ayers MS, 1998. A doubleblind placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans R Soc Trop Med Hyg 92: 663–666.
25. de la Tribonniere X, Valette M, Alfandari S, 1999. Oral nitazoxanide and paromycin inhalation for systemic cryptosporidiosis in a patient with AIDS. Infection 27: 232.
26. Giacometti A, Burzacchini F, Crioni O, Barchiesi F, Dini M, Scalise G, 1999. Efficacy of treatment with paromomycin, azithromycin, and nitazoxanide in a patient with disseminated cryptosporidiosis. Eur J Clin Microbiol Infect Dis 18: 885–889.
27. Yamamoto Y, Hakki A, Friedman H, Okubo S, Shimamura T, Hoffman PS, Rossignol J, 1999. Nitazoxanide, a nitrothiazolide antiparasitic drug, is an anti-Helicobacter pylori agent with anti-vacuolating toxin activity. Chemotherapy 45: 303–312.
28. Bicart-See A, Massip P, Linas MD, Datry A, 2000. Successful treatment with nitazoxanide of Enterocytozoon bieneusi microsporidiosis in a patient with AIDS. Antimicrob Agent Chemother 44: 167–168.
29. Gargala G, Delaunay A, Li X, Basseur P, Favenec L, Ballet JJ, 2000. Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite-infected HCT-8 enterocyticcells. J Antimicrob Chemother 46: 57–60.
30. Giacometti A, Cirioni O, Barchiesi F, Ancarani F, Scalise G, 2000. Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture. J Antimicrob Chemother 45: 453–456.
31. Rodriguez- García R, Rodríguez -Guzmán LM, Cruz del Castillo AH, 1999. Effectiveness and safety of mebendazole compared to nitazoxanide in the treatment of Giardia lamblia in children. Rev Gastroenterol Mex 64: 122–126.
32. Gonzalez-Ruiz A, Wright SG, 1998. Disparate amoebae. Lancet 351: 1672–1673.